Latest Posts
New Treatment Option Approved for Crohn’s After TNF Failure
The FDA has approved upadacitinib (Rinvoq) for adults with moderate to severe Crohn’s disease who haven’t responded well to TNF blockers. This gives patients and doctors a new treatment option with a different mechanism of action, backed by strong clinical trial data showing both symptom improvement and intestinal healing.
A Champion for IBD Patients: Dr. Cross Receives Prestigious Award
Dr. Raymond Cross has been named recipient of the 2026 Medical Champion Award by the Crohn’s & Colitis Foundation. His recognition highlights the importance of comprehensive, compassionate IBD care and offers hope for continued advances in treatment and patient advocacy.
New IBD Treatment Hope: EVerZom Raises $10M for Innovation
EVerZom secures $10 million to develop revolutionary exosome-based therapies for inflammatory diseases like Crohn’s and UC. Here’s what this breakthrough could mean for the IBD community and why it represents genuine hope for better treatments ahead.
New FDA-Approved Treatment Offers Hope for Tough Crohn’s Cases
The FDA’s approval of Rinvoq for Crohn’s disease offers new hope specifically for patients who haven’t responded to traditional anti-TNF therapies. This oral JAK inhibitor represents a different approach to controlling inflammation and could be a game-changer for those who have run out of treatment options.
New FDA-Approved IBD Treatment Offers Hope for Difficult Cases
The FDA has approved Rinvoq, a new once-daily oral treatment for moderate to severe Crohn’s disease and ulcerative colitis. This JAK inhibitor offers hope for patients who haven’t found success with traditional therapies, with some seeing improvement in as little as eight weeks.
Teen’s Solo World Flight Shows How We Rise Above Medical Challenges
A 15-year-old Australian pilot’s solo world flight after overcoming serious illness offers powerful inspiration for the IBD community. His Patient-to-Pilot mission shows how medical challenges can become sources of strength rather than limitations.
